JP2020200308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020200308A5 JP2020200308A5 JP2020087116A JP2020087116A JP2020200308A5 JP 2020200308 A5 JP2020200308 A5 JP 2020200308A5 JP 2020087116 A JP2020087116 A JP 2020087116A JP 2020087116 A JP2020087116 A JP 2020087116A JP 2020200308 A5 JP2020200308 A5 JP 2020200308A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperidin
- carboxylic acid
- benzodioxol
- benzimidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850133P | 2019-05-20 | 2019-05-20 | |
| US62/850,133 | 2019-05-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020200308A JP2020200308A (ja) | 2020-12-17 |
| JP2020200308A5 true JP2020200308A5 (enExample) | 2023-03-23 |
| JP7672201B2 JP7672201B2 (ja) | 2025-05-07 |
Family
ID=70775453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020087116A Active JP7672201B2 (ja) | 2019-05-20 | 2020-05-19 | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患治療のための組合せ |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12611401B2 (enExample) |
| EP (2) | EP3972596B1 (enExample) |
| JP (1) | JP7672201B2 (enExample) |
| CN (1) | CN113874019A (enExample) |
| AR (1) | AR118965A1 (enExample) |
| CA (1) | CA3140972C (enExample) |
| ES (1) | ES3039586T3 (enExample) |
| TW (1) | TW202110446A (enExample) |
| WO (1) | WO2020234726A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US12533312B2 (en) | 2011-02-04 | 2026-01-27 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| WO2021104021A1 (zh) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
| WO2021104022A1 (zh) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
| CA3163979A1 (en) * | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| GB202001856D0 (en) * | 2020-02-11 | 2020-03-25 | Inorbit Therapeutics Ab | Compounds useful in inhibiting ketohexokinase and methods of making and using the same |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) * | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| US20240252492A1 (en) | 2021-01-28 | 2024-08-01 | Carmot Therapeutics ,Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| US20220348564A1 (en) * | 2021-03-24 | 2022-11-03 | Eccogene (Shanghai) Co., Ltd. | Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same |
| WO2022219495A1 (en) * | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| CN117222644A (zh) * | 2021-04-12 | 2023-12-12 | 诺华股份有限公司 | 2-((4-((S)-2-(4-氯-2-氟苯基)-2-甲基苯并[d][1,3]二氧戊环-4-基)哌啶-1-基)甲基)-1-(((S)-氧杂环丁烷-2-基)甲基)-1H-咪唑衍生物作为GLP1受体激活剂治疗肥胖症 |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| CA3217720A1 (en) * | 2021-05-03 | 2022-11-10 | Xiaohui Du | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| CN116419923B (zh) * | 2021-08-24 | 2024-09-06 | 东宝紫星(杭州)生物医药有限公司 | 咪唑并环类化合物及其应用 |
| CN117940422A (zh) * | 2021-08-31 | 2024-04-26 | 辉瑞大药厂 | 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式 |
| KR20240056719A (ko) | 2021-09-08 | 2024-04-30 | 시오노기 앤드 컴파니, 리미티드 | 항비만 작용이 관여하는 질환의 예방 및 치료용 의약 |
| US20250236627A1 (en) * | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| JP2025506474A (ja) * | 2022-02-09 | 2025-03-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| JP2025505198A (ja) * | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN121002014A (zh) | 2022-12-15 | 2025-11-21 | 加舒布鲁姆生物公司 | 具有glp-1激动剂活性的化合物的盐和固体形式 |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| WO2024228213A1 (en) * | 2023-05-03 | 2024-11-07 | Dr. Reddy's Laboratories Limited | Crystalline forms of danuglipron |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025080818A1 (en) * | 2023-10-10 | 2025-04-17 | Sagimet Biosciences Inc. | Combinations of fasn inhibitors and glp-1 agonists for liver diseases |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US4465850A (en) | 1980-09-02 | 1984-08-14 | Merck & Co., Inc. | Treatment of brain injury due to gray matter edema with (indanyloxy) butanoic acids |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| US6488375B2 (en) | 1999-10-28 | 2002-12-03 | Ocular Sciences, Inc. | Tinted contact lens and method for making same |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| WO2003072197A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Acc inhibitors |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| EA011086B9 (ru) | 2004-05-12 | 2012-08-30 | Пфайзер Продактс Инк. | Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| WO2008065508A1 (en) | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Spiroketone acetyl-coa carboxylase inhibitors |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
| ES2380408T3 (es) | 2008-08-28 | 2012-05-11 | Pfizer Inc. | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| WO2010103437A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| CA2754523A1 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| MX2011010347A (es) | 2009-03-30 | 2011-11-29 | Transtech Pharma Inc | Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos. |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| GEP20135907B (en) | 2009-06-05 | 2013-08-12 | Pfizer | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| CN103221404B (zh) | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| DK2621493T3 (en) * | 2010-09-30 | 2016-10-24 | Pfizer | N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| TN2018000198A1 (en) * | 2015-12-29 | 2019-10-04 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| AR109179A1 (es) * | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| EP3713942B8 (en) * | 2017-11-21 | 2023-04-12 | Pfizer Inc. | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| ES2984510T3 (es) | 2018-07-05 | 2024-10-29 | Ntt Docomo Inc | Terminal, método de comunicación inalámbrica, estación base y sistema |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
-
2020
- 2020-05-15 CA CA3140972A patent/CA3140972C/en active Active
- 2020-05-15 WO PCT/IB2020/054637 patent/WO2020234726A1/en not_active Ceased
- 2020-05-15 ES ES20726962T patent/ES3039586T3/es active Active
- 2020-05-15 CN CN202080037376.3A patent/CN113874019A/zh active Pending
- 2020-05-15 EP EP20726962.2A patent/EP3972596B1/en active Active
- 2020-05-15 US US17/612,672 patent/US12611401B2/en active Active
- 2020-05-15 EP EP25168997.2A patent/EP4578460A3/en active Pending
- 2020-05-19 JP JP2020087116A patent/JP7672201B2/ja active Active
- 2020-05-19 TW TW109116550A patent/TW202110446A/zh unknown
- 2020-05-20 AR ARP200101424A patent/AR118965A1/es not_active Application Discontinuation
-
2026
- 2026-03-20 US US19/573,977 patent/US20260216152A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524831A5 (enExample) | ||
| US11780821B2 (en) | Inhibitors of fibroblast activation protein | |
| JP6435323B2 (ja) | 炎症性障害の治療のための新規化合物及びその医薬組成物 | |
| JP6454448B2 (ja) | ４−アミノ−２−（１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−イル）−６−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体及び心血管疾患を治療するためのｃＧＭＰモジュレーターとしてのそれぞれの（１Ｈ−インダゾール−３−イル）誘導体 | |
| TWI622589B (zh) | 細胞凋亡訊息調節激酶抑制劑 | |
| TWI695002B (zh) | 用於治療發炎病症之新穎化合物及彼等之醫藥組合物 | |
| HRP20201748T1 (hr) | Inhibitori diacilglicerol-aciltransferaze | |
| JP2021535126A5 (enExample) | ||
| KR101260162B1 (ko) | 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-ⅳ 저해제로서의 아미노테트라히드로피란 | |
| US20180256573A1 (en) | Trk-INHIBITING COMPOUND | |
| US20200216417A1 (en) | Inhibitors of fibroblast activation protein | |
| TW201720820A (zh) | B型肝炎核心蛋白質調節劑 | |
| WO2008044700A1 (en) | GSK-3β INHIBITOR | |
| TWI861497B (zh) | 作為cGAS抑制劑之具有C-連接環狀取代基之吡啶衍生物 | |
| AU2014283879B2 (en) | Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition thereof, preparation method and use thereof | |
| TW201629041A (zh) | 新穎化合物及其用於治療發炎病症及骨關節炎之醫藥組合物 | |
| TWI803600B (zh) | 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物 | |
| EP3541376B1 (en) | Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 | |
| JP6285873B2 (ja) | グリコーゲンシンターゼキナーゼ３ベータ阻害剤としての１ｈ−インダゾール−３−カルボキサミド化合物の使用 | |
| TW202102474A (zh) | 吡咯化合物 | |
| US12565496B2 (en) | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | |
| JP2010528009A (ja) | Ｃｓｆ−１ｒ阻害剤、組成物および使用方法 | |
| JP2020502058A (ja) | ジアシルグリセリドｏ−アシルトランスフェラーゼ２の阻害薬として有用なインダゾール誘導体 | |
| JP6404944B2 (ja) | ホスファチジルイノシトール３−キナーゼ阻害薬としてのピラジン誘導体 | |
| US20180291017A1 (en) | Aryl acylsulfonamides as blt1 antagonists |